ARHGAP33

Summary

ARHGAP33 (Rho GTPase activating protein 33, HGNC:23085) is a protein-coding gene on chromosome 19q13.12, encoding Rho GTPase-activating protein 33 (O14559). May be involved in several stages of intracellular trafficking.

This gene encodes a member of the sorting nexin family. Members of this family contain a phox (PX) domain, which is a phosphoinositide binding domain, and are involved in intracellular trafficking. Alternative splice variants encoding different isoforms have been identified in this gene.

Source: NCBI Gene 115703 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 210 total — 1 pathogenic
• MANE Select transcript: NM_001366178

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23085
Approved symbol	ARHGAP33
Name	Rho GTPase activating protein 33
Location	19q13.12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ39019, TCGAP
Ensembl gene	ENSG00000004777
Ensembl biotype	protein_coding
OMIM	614902
Entrez	115703

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 4 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000007510, ENST00000221905, ENST00000314737, ENST00000378944, ENST00000586918, ENST00000587984, ENST00000588248, ENST00000589133, ENST00000590893, ENST00000591438, ENST00000593034, ENST00000601474

RefSeq mRNA: 3 — MANE Select: NM_001366178 NM_001172630, NM_001366178, NM_052948

CCDS: CCDS12477, CCDS54254, CCDS92599

Canonical transcript exons

ENST00000007510 — 21 exons

Exon	Start	End
ENSE00000699235	35787168	35788822
ENSE00000699237	35786413	35787072
ENSE00000699423	35781150	35781252
ENSE00000699426	35780920	35781072
ENSE00000699429	35780421	35780498
ENSE00000862841	35784953	35785106
ENSE00001272823	35780757	35780816
ENSE00001272831	35780582	35780648
ENSE00001272918	35780211	35780333
ENSE00003475112	35782762	35782869
ENSE00003525507	35775564	35775664
ENSE00003547991	35784172	35784317
ENSE00003549758	35782373	35782517
ENSE00003553477	35785189	35785334
ENSE00003665226	35785409	35785483
ENSE00003696229	35777824	35777908
ENSE00003697304	35782597	35782679
ENSE00003701213	35778464	35778601
ENSE00003701934	35778280	35778360
ENSE00003702413	35777645	35777742
ENSE00003756824	35779032	35779124

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 98.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.2073 / max 263.4675, expressed in 1345 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175405	7.5895	1315
175404	0.3090	134
175406	0.1763	76
175403	0.1325	53

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.52	gold quality
ganglionic eminence	UBERON:0004023	97.86	gold quality
ventricular zone	UBERON:0003053	97.67	gold quality
right uterine tube	UBERON:0001302	97.50	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.93	gold quality
right frontal lobe	UBERON:0002810	96.43	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.41	gold quality
cerebellar hemisphere	UBERON:0002245	96.02	gold quality
adenohypophysis	UBERON:0002196	95.89	gold quality
cerebellar cortex	UBERON:0002129	95.70	gold quality
right testis	UBERON:0004534	95.32	gold quality
left testis	UBERON:0004533	95.31	gold quality
right ovary	UBERON:0002118	95.20	gold quality
pituitary gland	UBERON:0000007	94.81	gold quality
left ovary	UBERON:0002119	94.79	gold quality
nucleus accumbens	UBERON:0001882	94.44	gold quality
spinal cord	UBERON:0002240	94.12	gold quality
amygdala	UBERON:0001876	93.52	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.11	gold quality
cerebellum	UBERON:0002037	93.10	gold quality
caudate nucleus	UBERON:0001873	92.90	gold quality
body of uterus	UBERON:0009853	92.72	gold quality
endocervix	UBERON:0000458	92.52	gold quality
cingulate cortex	UBERON:0003027	92.52	gold quality
tibial nerve	UBERON:0001323	92.38	gold quality
testis	UBERON:0000473	92.32	gold quality
putamen	UBERON:0001874	92.24	gold quality
anterior cingulate cortex	UBERON:0009835	92.23	gold quality
type B pancreatic cell	CL:0000169	92.19	silver quality
sural nerve	UBERON:0015488	91.77	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6142	no	32.80
E-ANND-3	no	2.41

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

33 targeting ARHGAP33, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-7851-3P	98.72	64.88	980
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-6755-3P	98.61	66.90	834
HSA-MIR-7114-3P	98.42	66.53	569
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-6864-5P	98.38	66.59	1079
HSA-MIR-1180-5P	98.16	65.32	460
HSA-MIR-490-3P	97.79	65.54	606
HSA-MIR-203B-5P	97.24	68.54	543
HSA-MIR-6718-5P	97.24	68.15	553
HSA-MIR-6515-5P	97.08	65.48	1219

Literature-anchored findings (GeneRIF, showing 3)

• TCGAP interacts with Fyn and is phosphorylated by Fyn, with tyrosine-406 in the GTPase-activating protein (GAP) domain as a major Fyn-mediated phosphorylation site. (PMID:16777849)
• Results show that neurite outgrowth multiadaptor RhoGAP protein, NOMA-GAP, plays an essential role downstream of NGF in promoting neurite outgrowth and extension by recruiting SHP2 and activating Cdc42. (PMID:17664338)
• ARHGAP33 is associated with brain phenotypes of patients with schizophrenia. (PMID:26839058)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Arhgap33	ENSMUSG00000036882
rattus_norvegicus	Arhgap33	ENSRNOG00000024677
drosophila_melanogaster	CdGAPr	FBGN0032821
caenorhabditis_elegans		WBGENE00009800

Paralogs (3): ARHGAP31 (ENSG00000031081), ARHGAP32 (ENSG00000134909), ARHGAP30 (ENSG00000186517)

Protein

Protein identifiers

Rho GTPase-activating protein 33 — O14559 (reviewed: O14559)

Alternative names: Rho-type GTPase-activating protein 33, Sorting nexin-26, Tc10/CDC42 GTPase-activating protein

All UniProt accessions (4): O14559, A0A0A0MQQ9, K7EK14, K7EQI6

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in several stages of intracellular trafficking. Could play an important role in the regulation of glucose transport by insulin. May act as a downstream effector of RHOQ/TC10 in the regulation of insulin-stimulated glucose transport.

Subunit / interactions. Specifically interacts with CDC42 and RHOQ/TC10 through its Rho-GAP domain. Interacts with NEK6.

Similarity. Belongs to the PX domain-containing GAP family.

Isoforms (4)

UniProt ID	Names	Canonical?
O14559-1	1	yes
O14559-10	2
O14559-11	3
O14559-12	4

RefSeq proteins (3): NP_001166101, NP_001353107, NP_443180 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000198	RhoGAP_dom	Domain
IPR001452	SH3_domain	Domain
IPR008936	Rho_GTPase_activation_prot	Homologous_superfamily
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036871	PX_dom_sf	Homologous_superfamily
IPR051576	PX-Rho_GAP	Family

Pfam: PF00620, PF14604

UniProt features (37 total): compositionally biased region 11, region of interest 7, modified residue 6, splice variant 6, domain 3, sequence conflict 2, chain 1, site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14559-F1	54.54	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 350 (arginine finger; crucial for gtp hydrolysis by stabilizing the transition state)

Post-translational modifications (6): 8, 570, 636, 727, 1169, 1244

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9013148	CDC42 GTPase cycle
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013406	RHOQ GTPase cycle

MSigDB gene sets: 144 (showing top): GOBP_DENDRITE_DEVELOPMENT, MYOGENIN_Q6, CCAWYNNGAAR_UNKNOWN, GOBP_SYNAPSE_ASSEMBLY, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, CAGCTG_AP4_Q5, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_DENDRITE_MORPHOGENESIS, GOBP_REGULATION_OF_SYNAPSE_STRUCTURE_OR_ACTIVITY, GOBP_REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT

GO Biological Process (6): small GTPase-mediated signal transduction (GO:0007264), response to toxic substance (GO:0009636), protein transport (GO:0015031), regulation of dendritic spine morphogenesis (GO:0061001), regulation of postsynapse assembly (GO:0150052), signal transduction (GO:0007165)

GO Molecular Function (4): GTPase activator activity (GO:0005096), protein kinase binding (GO:0019901), phosphatidylinositol binding (GO:0035091), protein binding (GO:0005515)

GO Cellular Component (12): fibrillar center (GO:0001650), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), cytosol (GO:0005829), plasma membrane (GO:0005886), cell cortex (GO:0005938), postsynaptic density (GO:0014069), actin cytoskeleton (GO:0015629), protein-containing complex (GO:0032991), dendritic spine (GO:0043197), glutamatergic synapse (GO:0098978), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	3

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cytoplasm	3
regulation of postsynapse organization	2
cell periphery	2
intracellular signaling cassette	1
response to chemical	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
regulation of neuron projection development	1
regulation of anatomical structure morphogenesis	1
dendritic spine morphogenesis	1
regulation of synapse assembly	1
postsynapse assembly	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
kinase binding	1
anion binding	1
binding	1
nucleolus	1
nuclear lumen	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
asymmetric synapse	1
postsynaptic specialization	1
cytoskeleton	1
cellular_component	1
dendrite	1
neuron spine	1
postsynapse	1
synapse	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

668 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGAP33	SUCO	Q9UBS9	618
ARHGAP33	NEK6	Q9HC98	502
ARHGAP33	SORT1	Q99523	499
ARHGAP33	NTRK1	P04629	472
ARHGAP33	RALGAPB	Q86X10	462
ARHGAP33	SYNGAP1	Q96PV0	410
ARHGAP33	NCKAP1	Q9Y2A7	404
ARHGAP33	CDC42	P21181	390
ARHGAP33	ARHGEF2	Q92974	380
ARHGAP33	CRKL	P46109	370
ARHGAP33	CTTNBP2	Q8WZ74	366
ARHGAP33	FDXACB1	Q9BRP7	358
ARHGAP33	TSC2	P49815	353
ARHGAP33	ASXL3	Q9C0F0	353
ARHGAP33	ZNF292	O60281	353
ARHGAP33	CDC42BPG	Q6DT37	353

IntAct

5 interactions, top by confidence:

A	B	Type	Score
FYN	ARHGAP33	psi-mi:“MI:0915”(physical association)	0.510
ARHGAP33	FYN	psi-mi:“MI:0915”(physical association)	0.510
ADAM10	ARHGAP33	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGAP33	RAC1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): CYSRT1 (Two-hybrid), ARHGAP33 (Affinity Capture-MS), ARHGAP33 (Affinity Capture-MS), ARHGAP33 (Affinity Capture-RNA), ARHGAP33 (Proximity Label-MS), ARHGAP33 (Proximity Label-MS), ARHGAP33 (Affinity Capture-MS), ARHGAP33 (Two-hybrid), ARHGAP33 (Affinity Capture-MS), ARHGAP33 (Co-fractionation), ARHGAP33 (Affinity Capture-RNA), ARHGAP33 (Two-hybrid), ARHGAP33 (Two-hybrid), ARHGAP33 (Reconstituted Complex)

ESM2 similar proteins: A0A1B0GUA5, A0A286YF58, A0A494C0N9, A0A494C0Y3, A0A7I2V3R4, A0JNN8, A2ARS0, A2VDX9, A5PJP1, A6NGB7, A8MVW0, C9JTQ0, O14511, O14559, O35392, O35569, O43541, O60548, O70220, P0DPE3, Q08102, Q14V87, Q19A40, Q29RK8, Q2HJ59, Q3TYP4, Q5BLP8, Q5T442, Q63244, Q6F5E0, Q6QNY0, Q6VUP9, Q80WY3, Q80XF7, Q8BQU6, Q8K025, Q8K071, Q8TD94, Q8WY41, Q8WZ71

Diamond homologs: A0A0G2JTR4, A1A4S6, A2AB59, A2RUV4, A4IF90, A4II46, A6QNS3, A6X8Z5, A7KAX9, A7YY57, A8WRJ2, D3ZFJ3, E7EZG2, E7F3F0, F1LXF1, O14559, O94466, P11274, P15882, P30337, P34288, P38339, P46941, P52757, P55194, P81128, P97393, Q03070, Q08DP6, Q10164, Q12979, Q13017, Q15311, Q17QN0, Q20498, Q2M1Z3, Q3TBD2, Q3UIA2, Q52LW3, Q53QZ3

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
FYN	down-regulates	ARHGAP33	phosphorylation
ARHGAP33	“down-regulates activity”	RAC1	“gtpase-activating protein”

Disease & clinical

Clinical variants and AI predictions

ClinVar

210 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	174
Likely benign	11
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
625761	GRCh37/hg19 19q13.11-13.12(chr19:35043556-36316644)	Pathogenic

SpliceAI

3074 predictions. Top by Δscore:

Variant	Effect	Δscore
19:35775662:GTG:G	donor_gain	1.0000
19:35778357:TCAG:T	donor_loss	1.0000
19:35778359:AGG:A	donor_loss	1.0000
19:35778458:CCACA:C	acceptor_loss	1.0000
19:35778459:CACAG:C	acceptor_loss	1.0000
19:35778461:CAG:C	acceptor_loss	1.0000
19:35778462:A:T	acceptor_loss	1.0000
19:35778462:AG:A	acceptor_gain	1.0000
19:35778463:GG:G	acceptor_gain	1.0000
19:35778463:GGGCC:G	acceptor_gain	1.0000
19:35778544:G:GT	donor_gain	1.0000
19:35778597:CCCAG:C	donor_loss	1.0000
19:35778598:CCAG:C	donor_loss	1.0000
19:35778599:CAG:C	donor_loss	1.0000
19:35778600:AGG:A	donor_loss	1.0000
19:35778601:GGTAA:G	donor_loss	1.0000
19:35778602:G:C	donor_loss	1.0000
19:35778603:T:A	donor_loss	1.0000
19:35779122:G:GT	donor_gain	1.0000
19:35780192:C:G	acceptor_gain	1.0000
19:35780193:A:AG	acceptor_gain	1.0000
19:35780194:T:G	acceptor_gain	1.0000
19:35780198:A:AG	acceptor_gain	1.0000
19:35780199:C:G	acceptor_gain	1.0000
19:35780204:A:AG	acceptor_gain	1.0000
19:35780205:T:G	acceptor_gain	1.0000
19:35780206:TTCA:T	acceptor_loss	1.0000
19:35780207:TCAGC:T	acceptor_loss	1.0000
19:35780208:CAG:C	acceptor_loss	1.0000
19:35780209:A:AG	acceptor_gain	1.0000

AlphaMissense

4762 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000340213 (19:35783492 A>G), RS1000361674 (19:35777196 C>T), RS1000367743 (19:35773960 C>A), RS1000943872 (19:35782309 G>A), RS1001062366 (19:35779511 C>T), RS1001096488 (19:35779356 A>T), RS1001143225 (19:35787792 C>T), RS1001306726 (19:35779035 C>T), RS1001380939 (19:35776189 G>T), RS1001413605 (19:35775762 C>A,G), RS1001435555 (19:35773914 G>A,C,T), RS1001441899 (19:35784773 C>T), RS1001865566 (19:35773629 G>C), RS1002135956 (19:35786612 C>A,T), RS1002320063 (19:35774432 A>G)

Disease associations

OMIM: gene MIM:614902 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (2): breast ductal adenocarcinoma (MONDO:0005590), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003255_11	Urinary albumin-to-creatinine ratio	5.000000e-06
GCST008022_4	Umami taste perception in obesity with metabolic syndrome	8.000000e-06
GCST010703_277	Brain morphology (MOSTest)	2.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007778	urinary albumin to creatinine ratio
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
titanium dioxide	increases expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
muconaldehyde	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
calfactant	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	affects cotreatment, decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Testosterone	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Gold Compounds	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	decreases expression	1
Nanotubes, Carbon	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

13 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery